Achmea Investment Management B.V. Trims Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Achmea Investment Management B.V. decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 24.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,115 shares of the company's stock after selling 701 shares during the quarter. Achmea Investment Management B.V.'s holdings in IDEXX Laboratories were worth $888,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Sagespring Wealth Partners LLC purchased a new stake in IDEXX Laboratories in the first quarter worth about $229,000. Banque Transatlantique SA purchased a new stake in shares of IDEXX Laboratories in the fourth quarter worth $2,681,000. Wealth Enhancement Advisory Services LLC raised its position in shares of IDEXX Laboratories by 13.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 25,553 shares of the company's stock valued at $10,731,000 after purchasing an additional 2,931 shares during the period. Steward Partners Investment Advisory LLC raised its position in shares of IDEXX Laboratories by 9.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,436 shares of the company's stock valued at $1,007,000 after purchasing an additional 218 shares during the period. Finally, GAMMA Investing LLC lifted its stake in shares of IDEXX Laboratories by 42.7% during the 1st quarter. GAMMA Investing LLC now owns 2,187 shares of the company's stock valued at $918,000 after buying an additional 654 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Insiders Place Their Bets

In related news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the sale, the director directly owned 1,801 shares in the company, valued at $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.98% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on IDXX shares. Leerink Partners raised their price target on IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a report on Wednesday, June 11th. Jefferies Financial Group assumed coverage on IDEXX Laboratories in a report on Tuesday. They issued a "buy" rating and a $625.00 price target on the stock. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Stifel Nicolaus lifted their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Finally, Morgan Stanley boosted their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $554.78.

IDEXX Laboratories Trading Up 0.9%

Shares of NASDAQ:IDXX traded up $4.99 during trading on Tuesday, reaching $541.33. The company's stock had a trading volume of 317,701 shares, compared to its average volume of 643,799. The stock has a market capitalization of $43.53 billion, a PE ratio of 50.19, a price-to-earnings-growth ratio of 3.88 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $546.58. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31. The firm's 50 day simple moving average is $501.61 and its two-hundred day simple moving average is $451.67.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The company's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.71 earnings per share. On average, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.